Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
International Multicentre Study of <i>Candida auris</i> Infections
oleh: Nirav Pandya, Yasemin Cag, Nenad Pandak, Abdullah Umut Pekok, Aruna Poojary, Folusakin Ayoade, Teresa Fasciana, Anna Giammanco, Hulya Caskurlu, Dhanji P. Rajani, Yogesh Kumar Gupta, Ilker Inanc Balkan, Ejaz Ahmed Khan, Hakan Erdem
Format: | Article |
---|---|
Diterbitkan: | MDPI AG 2021-10-01 |
Deskripsi
<b>Background:</b><i>Candida auris</i> has emerged globally as a multi-drug resistant yeast and is commonly associated with nosocomial outbreaks in ICUs. <b>Methods:</b> We conducted a retrospective observational multicentre study to determine the epidemiology of <i>C. auris</i> infections, its management strategies, patient outcomes, and infection prevention and control practices across 10 centres from five countries. <b>Results:</b> Significant risk factors for <i>C. auris</i> infection include the age group of 61–70 years (39%), recent history of ICU admission (63%), diabetes (63%), renal failure (52%), presence of CVC (91%) and previous history of antibiotic treatment (96%). <i>C. auris</i> was commonly isolated from blood (76%). Echinocandins were the most sensitive drugs. Most common antifungals used for treatment were caspofungin (40%), anidulafungin (28%) and micafungin (15%). The median duration of treatment was 20 days. Source removal was conductedin 74% patients. All-cause crude mortality rate after 30 days was 37%. Antifungal therapy was associated with a reduction in mortality (OR:0.27) and so was source removal (OR:0.74). Contact isolation precautions were followed in 87% patients. <b>Conclusions:</b><i>C. auris</i> infection carries a high risk for associated mortality. The organism is mainly resistant to most azoles and even amphotericin-B. Targeted antifungal therapy, mainly an echinocandin, and source control are the prominent therapeutic approaches.